Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2460

Efficient and specific gene knockdown by siRNAs produced in bacteria

Inventors: Judy Lieberman, Linfeng Huang

Invention Types: Research Tool, Therapeutics

Research Areas: Immunology

Keywords: Drug Delivery, siRNA

For More Information Contact:  Dietz, Ryan

 

Invention Description:

siRNAs are an indispensable tool to investigate gene function in eukaryotic cells and may be used for therapeutic purposes to knock down genes implicated in disease. Most siRNAs have been produced by chemical synthesis. Researchers at Boston Children’s have developed a simple method to produce highly potent recombinant siRNAs in Escherichia coli using methods accessible to any laboratory capable of producing recombinant proteins. This method relies on ectopic expression of p19, an siRNA-binding protein found in a plant virus. When expressed in E. coli, p19 stabilizes ~21-nt siRNAs produced by bacterial RNase III (“prokaryotic siRNAs”). siRNAs generated in bacteria expressing p19 and a hairpin RNA encoding 200 or more nucleotides of a target gene contain multiple sequences from the target gene sequence. Prokaryotic siRNAs can be easily purified from bacterial lysates using methods that could be adapted for large scale fermentation. When mammalian cells are transfected with low nanomolar concentrations of prokaryotic siRNAs, target gene knockdown is reproducibly reduced by ~90% without immunogenicity or off-target effects. Because bacterially produced siRNAs contain multiple sequences against a target gene, they may be especially useful for suppressing polymorphic cellular or viral genes.


Huang L, Lieberman J. Production of highly potent recombinant siRNAs in
Escherichia coli. Nat Protoc. 2013 Dec;8(12):2325-36. doi:
10.1038/nprot.2013.149. Epub 2013 Oct 31. PubMed PMID: 24177290.

Applications:

• A renewable method to produce highly potent siRNAs in bacteria suitable for research or therapeutic use. |

• Especially useful for knockdown of polymorphic cellular or viral genes. |

• Research tool companies could produce kits to generate a p19-siRNA expression plasmid and/or to express, isolate and purify prokaryotic siRNAs. |

• Research service companies could provide p19-siRNA plasmids reliable for knocking down any gene. |

• Generate siRNA libraries based on gene expression of specific cell types or diseases for use in screening to identify drug targets.

Competitive Advantages:

• This method shows for the first time that highly potent and pure siRNAs can be produced in a living organism. |

• Synthetic siRNAs often require testing multiple constructs to achieve variable degrees of knockdown with associated reagent, labor and time costs. |

• Prokaryotic siRNAs can be readily engineered to knock down any eukaryotic gene efficiently and specifically in mammalian cells without appreciable off-target effects and without detectable immunostimulation. |

• Scaled up production using recombinant techniques could be cost effective for in vivo uses.

Business Opportunity:

Non-exclusive license

Key Publications: Huang L, Jin J, Deighan P, Kiner E, McReynolds L, Lieberman J. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013 Apr;31(4):350-6.

Huang L, Lieberman J. Production of highly potent recombinant siRNA in Escherichia coli. Nat. Protoc. 2013 Dec;8(12).

IPStatus: Patented